Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 1;6(3):354-357.
doi: 10.1001/jamacardio.2020.5921.

Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults With Diabetes

Michael C Honigberg  1 , Ravi B Patel  2 , Ambarish Pandey  3 , Gregg C Fonarow  4   5 , Javed Butler  6 , Darren K McGuire  3 , Muthiah Vaduganathan  7
Affiliations

Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults With Diabetes

Michael C Honigberg et al. JAMA Cardiol. .

Abstract

This cohort study evaluates the association of heart failure and ischemic heart disease with diabetes complications.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Honigberg reports a grant from the National Institutes of Health outside the submitted work. Dr Fonarow reports research funding from the National Institutes of Health and personal fees from Abbott Laboratories, Amgen, AstraZeneca, Bayer, CHF Solutions, Janssen, Medtronic, Merck, and Novartis outside the submitted work. Dr Butler reports research support from the National Institutes of Health, Patient-Centered Outcomes Research Institute, and the European Union outside the submitted work and serves as a consultant for Amgen, Abbott Laboratories, Array BioPharma, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squib, CVRx, G3 Pharmaceutical, Innolife, Janssen, LivaNova, American Regent, Medtronic, Merck, Novartis, Relypsa, StealthPeptide, scPharmaceuticals, Vifor Pharma, and ZS Pharma. Dr McGuire reports personal fees and honoraria for trial leadership and consultancy from Boehringer Ingelheim, Sanofi, AstraZeneca, Merck & Co, Novo Nordisk, and Eli Lilly and Co; for trial leadership from CSL Behring, Pfizer, Lexicon, and GlaxoSmithKline; and for consultancy from Applied Therapeutics, Metavant, and Afimmune outside the submitted work. Dr Vaduganathan has received a KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst and personal fees for consulting for or serving on the advisory boards of Amgen, AstraZeneca, Baxter Healthcare, Bayer, Boehringer Ingelheim, Cytokinetics, and Relypsa outside the submitted work, and participates on clinical end point committees for studies sponsored by Novartis and the National Institutes of Health. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Estimated Incidence Rates of Hospitalization for Heart Failure (HF) and Ischemic Heart Disease in US Adults With Diabetes Between 1995 and 2015
Increase in incidence of heart failure hospitalization from 2013 to 2015 was not statistically significant (P = .27).
Figure 2.
Figure 2.. Estimated Incidence Rates of Hospitalization for Heart Failure (HF) in US Adults With Diabetes Between 1995 and 2015 by Age and by Sex
See this image and copyright information in PMC

References

    1. McAllister DA, Read SH, Kerssens J, et al. . Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without diabetes mellitus. Circulation. 2018;138(24):2774-2786.https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&li... doi:10.1161/CIRCULATIONAHA.118.034986 - DOI - PMC - PubMed
    1. Segar MW, Vaduganathan M, Patel KV, et al. . Machine learning to predict the risk of incident heart failure hospitalization among patients with diabetes: the WATCH-Diabetes Risk Score. Diabetes Care. 2019;42(12):2298-2306.https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&li... doi:10.2337/dc19-0587 - DOI - PMC - PubMed
    1. Zelniker TA, Wiviott SD, Raz I, et al. . SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31-39.https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&li... doi:10.1016/S0140-6736(18)32590-X - DOI - PubMed
    1. US Centers for Disease Control and Prevention . US Diabetes Surveillance System and Diabetes Atlas. Accessed January 5, 2020. https://gis.cdc.gov/grasp/diabetes/diabetesatlas.html
    1. Gregg EW, Hora I, Benoit SR. Resurgence in diabetes-related complications. JAMA. 2019;321(19):1867-1868.https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&li... doi:10.1001/jama.2019.3471 - DOI - PubMed

Publication types